EcoDrugPlus

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSOSIG00000022174
Gene Symbol: CCR9
1 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSOSIG00000015690
Gene Symbol: CXCR1
1 Cross references
275 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOSIG00000020459
Gene Symbol: CFTR
1 Cross references
214 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSOSIG00000007652
Gene Symbol: DNMT1
1 Cross references
210 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSOSIG00000009943
Gene Symbol: TOP1
1 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSOSIG00000004367
Gene Symbol: TOP2B
1 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSOSIG00000009347
Gene Symbol: TOP1A
1 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSOSIG00000005332
Gene Symbol: EML4
1 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSOSIG00000007259
Gene Symbol: EPHA3
1 Cross references
210 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSOSIG00000022433
Gene Symbol: F2RL3
1 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSOSIG00000011659
Gene Symbol: FAUA
1 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase A

Ensembl ID : ENSOSIG00000007417
Gene Symbol: FYNA
1 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).